BFRI - biofrontera-us.com Debt to Book Capitalization Ratio

Biofrontera Inc. management is expanding its distribution network and enhancing physician qualifications to achieve profitability, leveraging stable demand for lasers and prescription products in the US. The ratio of debt capital to book capitalization demonstrates financial leverage, where the 1.32 indicator reflects the metric's balance. Business growth is driven by partnerships with clinics to implement Ameluz therapy and the acquisition of software patents.

Biofrontera Inc. (BFRI) dominates the photodynamic therapy niche through the synergy of its Ameluz drug and specialized equipment. This business model is reflected in the capital structure, where the debt-to-book value ratio determines the degree of financial autonomy. This metric measures the company's reliance on borrowed funds relative to its equity. Low leverage minimizes bankruptcy risks but may constrain expansion rates. Analyzing the ratio of liabilities to book capitalization allows for an assessment of the development strategy's sustainability.